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Abstract
Applications of Genome Polymorphism Scans range from the relatively simple such as gender
determination and confirmation of biological relationships, to the relatively complex such as
determination of autozygosity and propagation of genetic information throughout pedigrees. Unlike
nearly all other clinical DNA tests, the Scan is a universal test – it covers all people and all genes.
In balance, I argue that the Genome Polymorphism Scan is the most powerful, affordable clinical
DNA test available today.
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Introduction
Already today, and much more so in the future, DNA
sequence information will be used to establish and con-
firm diagnoses, to help determine treatment, and to pre-
vent disease through presymptomatic identification of
genetic risk. Many distinguished authors have recently
elaborated upon these points [1-3]. In this article, I
describe the many clinical applications of Genome Poly-
morphism Scans along with some technical aspects of the
Scans and limitations in their use.
Genome Polymorphism Scans (hereafter Scans) are
defined as the typing of a set of DNA polymorphisms
spanning the length of each chromosome within a
genome. The Scans are usually performed on individual
DNA samples, but occasionally also on pools of DNAs.
The two key parameters of the Scans are the type(s) of pol-
ymorphisms utilized and the density of polymorphisms.
In addition to the actual genotypes, other important data
can and should be collected during the Scans (Table 1).
Genotyping methods that allow the collection of all these
data are preferable.
Applications of Genome Polymorphism Scans
The many clinical applications of the Scans are described
in the following paragraphs and listed in Table 2. The
applications were developed through the work of many
different investigators as well as through the performance
in my lab of Scans on over 100,000 people. The applica-
tions are listed approximately in the order of lowest to
highest numbers of polymorphisms required.
A simple, but important, application is the determination
of gender. This is achieved through the typing of polymor-
phisms on the sex chromosomes. Males with normal kary-
otype, for example, should not be heterozygous for
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polymorphisms exclusive to the X chromosome, and nor-
mal females should show no signals for polymorphisms
exclusive to the Y chromosome. Confirmation of gender is
one good way to monitor sample mislabeling and rates of
genotyping error.
The Scans also permit detection and confirmation of close
family relationships. Monozygotic twin, parent-child, full
sibling, and half sibling relationships can usually be
clearly distinguished from each other and from other rela-
tionships with Scans of even modest polymorphism den-
sity [4-6]. Pairs of more distantly related individuals can
often be distinguished from unrelated pairs, but the exact
nature of the relationship is difficult to determine. Com-
parison of relationships derived from the Scans with
patient self-reported family trees should nearly always
result in accurate pedigrees. Confirmation of reported
pedigree structure is another good way to check for sam-
ple mislabeling, and is vital for the confident use of pedi-
grees in further analyses.
Even very low density versions of the Scans can be used to
"fingerprint" individuals [7,8]. Such individual tags have
important application in criminal investigations and
identification of remains. Some people are already begin-
ning to advocate DNA fingerprinting of all individuals [9].
A key question with identity testing is whether the data
generated for clinical purposes should be available to gov-
ernments and/or law enforcement organizations. Simi-
larly, we need to decide whether different polymorphisms
should be used for clinical Scans and forensic fingerprints.
In principle, Scan data can also be used to detect chimeric
and mosaic individuals. Much depends on the ability of
the genotyping method to detect weak second or third
alleles. Such alleles may arise from somatic mutation,
sharing of cells between dizygotic twins, fetal-maternal
cell transfer, and a number of other mechanisms [10-12].
The presence of foreign cells may cause autoimmune and
other health problems [13,14]. It is difficult to distinguish
laboratory contamination of a DNA sample from true chi-
merism or mosaicism. In some cases Scan data from close
family members would help to resolve the two possibili-
ties. This application of Scan data is probably the least
well established of all those described in this article.
Genome Polymorphism Scans can be used to identify
chromosomal or segmental aneusomies. Three or more
copies of a chromosomal segment in an individual may
often be detected as genotypes with more than two alleles
or as heterozygous genotypes with unequal allele detec-
tion signals. A good example is the duplication on chro-
mosome 17p that is responsible for Charcot Marie Tooth
disease type 1A [15]. A single copy of a chromosomal seg-
Table 1: Data that may be collected for each genotype in a Scan
1. The identities of the alleles (as complete as possible) at each locus
2. The confidence in the allele calls
3. The detection signals for each allele and whether these signals are normal or are unexpectedly strong or weak
4. The (rare) presence of three or more alleles for multiallelic polymorphisms
5. The expected frequency of the observed genotype given known allele frequencies for the individual's population
6. When genotypes are available from family members, whether the allele transmission patterns between generations are consistent with Mendel's 
rules
Table 2: Minimum STRPa densities required for Scan applications
APPLICATION MINIMUM NUMBERS OF STRPS
Gender determination 10
Family tree construction 10
Individual identification 10
Chimerism discovery 100
Aneusomy detection 500
Uniparental disomy detection 500
Autozygosity determination 500
Inbreeding measurement 500
Linkage mapping 500
Geoancestry estimation 500
Haplotype determination 500
Propagation of genetic information 1000
Genotyping error detection 1000
Association mapping 2000
a A rough estimate of the equivalent numbers of diallelic polymorphisms can be obtained by multiplying the numbers of STRPs by 4.Biology Direct 2006, 1:16 http://www.biology-direct.com/content/1/1/16
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ment may be identified in at least three ways: as an unu-
sually weak allele signal compared to sequences on other
chromosomes or compared to the same polymorphism in
other individuals [16], improbably long stretches of adja-
cent polymorphisms that all appear to be homozygous
[17-19], and/or Mendelian parent to child transmission
inconsistencies [20].
Chromosomal translocations and inversions may at least
occasionally be detected through the Scans. For transloca-
tions, if family size is sufficiently large, expected linkage
between adjacent polymorphisms that have been sepa-
rated by the translocation may be diminished or absent.
For inversions, highly improbably tight double recombi-
nation events may be observed [21], or detection may be
achieved through association with specific alleles [22].
Uniparental disomy may be detected through Mendelian
transmission errors or, in the case of isodisomy, through
improbably long chromosomal stretches of homozygous
genotypes [23]. A particularly nice example was involved
in the discovery of mutations in the lamin A gene as the
cause of Hutchinson-Gilford progeria [24]. Since all cases
of this disease are caused by de novo mutations, the lamin
A gene could not have been mapped by linkage; it was
only mapped through observation of uniparental isodis-
omy on chromosome 1q.
Homozygosity of a polymorphism, especially homozy-
gosity for a rare allele or a contiguous chromosomal
stretch of homozygous polymorphisms may indicate
autozygosity. Autozygosity is the inheritance of the same
chromosomal segment, originally from a more distant
ancestor, through both mother and father [25]. Because of
population bottlenecks and resulting relatively low
genetic diversity in humans, autozygosity for short chro-
mosomal segments is found in everyone. Surprisingly,
long autozygous segments spanning up to many tens of
mb are also relatively common [26]. Autozygous regions
are important clinically because many disease risk alleles
have much more potent effects when present in two cop-
ies than when present in only one copy [27-30]. When
Scan data from parents is unavailable, cytogenetics or
comparative genomic hybridization might be required to
distinguish a deletion from autozygosity or uniparental
isodisomy.
Inbreeding, at least at higher levels, can be detected
through Scans [31]. Inbreeding levels in the offspring of
prospective couples can also be estimated through Scan
data. Even modest levels of inbreeding may have substan-
tial effects on health [32,33].
For many Mendelian disorders, mutations within any of
two or more unlinked genes can cause disease. A good
example is early onset breast/ovarian cancer where muta-
tions in two genes, BRCA1  on chromosome 17 and
BRCA2 on chromosome 13, are causative [34,35]. If Scans
have been performed on family members, then it will
often be possible through standard linkage analysis to
determine which gene is involved in a particular family.
This will substantially reduce testing costs by allowing
labs to focus on the correct gene. For this purpose, fami-
lies do not have to be large enough to obtain lod scores
above 3.0, but rather just large enough to indicate which
gene likely carries the mutation. In many cases, only two
affected family members will be sufficient. In the case of
rare recessive disorders in isolated populations, a single
affected individual will often be sufficient.
The Scans also allow approximate determination of
geoancestry [36,37]. By geoancestry, I mean the geograph-
ical origin of a person's ancestors at about the time of
Columbus (~1500). An example is presented in Table 3.
Beyond personal curiosity, geoancestry is important in
cataloging which disease risk alleles an individual may
carry. For example, a person of only Northern European
ancestry is unlikely to carry the sickle cell anemia muta-
tion, and a person of only African ancestry is unlikely to
carry the CFTR  ΔF508 mutation. However, an African
American with 30% European ancestry has a much higher
probability of carrying this CFTR mutation. As polymor-
phism density in the Scans increases and as our ability to
analyze Scan data for geoancestry improves, it will
become possible to confidently determine not only over-
Table 3: Geoancestya of selected research subjects from the Dominican Republic
Subject Caucasian African Native American Asian
A .02 .95 .02 .01
B .91 .01 .08 .00
C .01 .00 .99 .00
D .89 .08 .02 .01
E .28 .68 .04 .00
F .42 .45 .13 .00
G .17 .46 .36 .01
a Subjects underwent 400 STRP Genome Polymorphism Scans [63]. Geoancestry was determined using STRUCTURE [64] and data from the 
Human Diversity Panel [65].Biology Direct 2006, 1:16 http://www.biology-direct.com/content/1/1/16
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all geoancestry, but also geoancestry of individual chro-
mosomal segments [38].
Another simple, but very important consequence of per-
forming Scans in families is that haplotypes will often be
determined unambiguously. When both parents and a
child are typed, the phase in the child can be obtained for
all situations except when all three individuals are hetero-
zygous with the same genotype. Haplotypes are more use-
ful than genotypes in many clinical situations, like for
example, in the prediction through association of specific
mutations that a patient is likely to carry [[39] and see
below].
The Scans permit propagation of genetic information
through families. Once a single family member is identi-
fied as carrying a disease risk allele on a particular haplo-
typic background, then other family members who carry
the risk allele may be identified as those who carry this
same haplotype [40,41]. When disease risk alleles are rel-
atively common in a population, then screening all indi-
viduals may be cost effective, but when the risk allele is
rare, then it is impractical to screen everyone [42,43].
When several different genes are responsible for a disorder
and/or when disease genes have many exons, it is expen-
sive to identify the causative mutation. It is unconsciona-
ble to repeat this costly analysis for each family member.
The presence of strong positive interference in humans
[44] makes the propagation process more reliable because
double recombination events within small genetic inter-
vals (roughly ≤5 cM) are extremely rare.
A corollary of the propagation of sequence information
through kindreds, is the identification (and hence elimi-
nation) of genotyping errors [45]. A simple example is
shown in figure 1. Each living family member has under-
gone the Scan. Multiallelic polymorphisms A and B from
the Scan are 5 cM apart and flank a disease gene with rare
disease allele D and normal allele N. Typing of the disease
locus in the grandmother and mother establishes the hap-
lotypes in the mother. Assuming that the Scan genotypes
are correct, and barring highly improbable mutation, gene
conversion, or double recombination, then the grand-
daughter must have inherited the haplotypes shown and
must carry the D allele. If genotyping at the disease locus
in the daughter yields N, N, then an error is very likely and
the test should be repeated.
Finally, through association (linkage disequilibrium) the
Scans may be used to suggest which specific mutations a
patient is likely to carry. This strategy has been firmly
established by the finding that many (probably the great
majority) of mutations responsible for disease have arisen
from a single founder on a single haplotypic background
(as opposed to recurrent mutations at a mutation
hotspot) [46-48]. Detection of this haplotype through the
Scans will often define the exact mutation in an affected
individual and will often predict the presence of a specific
mutation in an unaffected carrier. For recent mutations,
such disequilibrium may extend several mb. For older
mutations, higher polymorphism densities in the Scans
will be required.
Markers used in Genome Polymorphism Scans
Considering abundance and genotyping cost, there are
today only two possible choices for polymorphisms to be
used in the Scans: multiallelic short tandem repeat (STR;
also called microsatellite) polymorphisms or diallelic pol-
ymorphisms (either substitutions (SNPs) and/or indels).
A comparison of the properties of the two types of poly-
morphisms is shown in Table 4. Diallelic polymorphisms
have the advantages of generally lower genotyping costs
and greater abundance. Multiallelic polymorphisms have
the advantages of higher informativeness, the apparent
ability to detect linkage disequilibrium at much greater
distances [49], and the presence of rare alleles which help
in the detection of biological relationships, inbreeding
and aneusomies, and which increase haplotypic diversity.
Considering all these factors, I currently favor the com-
bined use of both types of polymorphisms in the Scans.
Others have demonstrated the usefulness of combina-
tions of both types [50-52].
Although some applications of the Scans, like for example
individual identification, can be achieved with quite small
numbers of polymorphisms (Table 2), higher polymor-
phism density is always preferable. Higher polymorphism
densities yield greater power for all applications. More
distant biological relationships can be established, lower
levels of inbreeding can be reliably measured, and shorter
Table 4: Average properties of human multiallelic and diallelic polymorphisms
PROPERTY MULTIALLELIC DIALLELIC
Number in human gene pool 106 12 × 106
Spacing 3000 bp 250 bp
Heterozygositya 75% 30%
Rare allelesa Yes No
a For the markers that would typically be used in Genome  Polymorphism Scans.Biology Direct 2006, 1:16 http://www.biology-direct.com/content/1/1/16
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duplications and deletions can be detected. Detection of
linkage disequilibrium is especially sensitive to polymor-
phism density.
Polymorphism density in the Scans will almost certainly
be limited by cost. As seen by the data in Table 2, the min-
imum effective polymorphism density for clinical applica-
tions would probably be about 1STRP per 4 cM (~1000
STRPs total). The fraction of health care spending that
people will be willing to devote to clinical genetic testing
is uncertain. Assuming it is 1% or about $60 per year per
person, then I believe that the total costs of the Scans
should be no more than a few hundred dollars. Despite
the crude nature of these estimates, it is important to note
that 4 cM density is readily achievable for a few hundred
dollars even at today's genotyping costs. As genotyping
technology improves, much higher densities should
become possible.
A few other factors may affect polymorphism choice and
density. For example, several have suggested that local
polymorphism density in the Scans should parallel gene
density [53,54]. Also, as the number of known common
disease risk alleles increases, at least many of the polymor-
phisms in the Scans could be comprised of polymor-
phisms that would do the double duty of achieving the
applications described in this article and at the same time
help to outline the patient's risk for specific health prob-
lems. Examples are common apolipoprotein E, β-globin,
and hemochromatosis polymorphisms. Polymorphisms
may also be chosen so as to determine the orientation of
large scale chromosomal rearrangements [22]. Finally, as
polymorphism density in the Scans increases, it may
become important to consider the location of the poly-
morphisms relative to strong recombination hot spots.
Limitations and obstacles
Some applications described in this article, for example
the propagation of information throughout kindreds and
the determination of haplotypes, require the cooperation
of family members. The power of these applications is
diminished by the absence of DNA from some family
members. A public health system in which DNA is rou-
Hypothetical example of detection of genotyping errors through Genome Polymorphism Scans Figure 1
Hypothetical example of detection of genotyping errors through Genome Polymorphism Scans. Shown are two 
multiallelic polymorphisms 5 cM apart from a Scan, A and B, which flank a disease locus (indicated by the arrow in the grand-
daughter) with a rare disease allele D and normal allele N. Unambiguous haplotypes are determined by inspection in both 
mother and granddaughter. Barring a highly improbable event, the granddaughter will carry the D allele on the haplotype inher-
ited from her mother. Any test result in the granddaughter at the disease locus which does not yield a D, N genotype is very 
likely incorrect and should be repeated.
A1,A2
D,N
B1,B2
A1
D
B1
A3
N
B3
A1
B1
A4
B4
A1,A4
B2,B4Biology Direct 2006, 1:16 http://www.biology-direct.com/content/1/1/16
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tinely collected from all patients, for example at birth,
would clearly increase the power of the Scans.
Much new software and many new data management sys-
tems will need to be created to make maximal use of the
Scan data. Existing software can certainly be used as a
starting point, but much theoretical and applied research
still remains.
Propagation of genetic information throughout families
will not permit the detection of most new mutations.
Compared to inherited mutations that increase the risk for
disease, new mutations that influence disease are rare, but
of course do continuously occur.
Other genome wide tests such as gene expression analysis,
cytogenetics and comparative genome hybridization
(CGH) can also be considered for widespread application
in patients. Of these other tests, CGH is probably the
leader. CGH using high density arrays [55-58] permits
much higher resolution mapping of aneusomies than
Scans, and will likely find wide application in many indi-
viduals. It may even be possible to combine polymor-
phism Scans with copy number determination [59].
What about just sequencing the entire genome of each
patient? There has been much recent discussion and
research spending directed toward the goal of sequencing
an individual's genome for about $1000 [60-62]. If very
low cost sequencing were available, it would clearly
accomplish nearly all the applications of the Scans and
would also permit the detection of new mutations. How-
ever, it currently costs roughly $10 million to sequence a
person's genome with a relatively high level of complete-
ness and accuracy. It may be many decades before we
achieve the "$1000 genome". Also, even when such tech-
nology becomes available, some level of sequencing
errors will inevitably be present. The Scans might still be
useful in the detection of these errors (see figure 1).
Over at least the next few decades, a more realistic sce-
nario than the "$1000 genome" may be technology for
partial, but significant, sequencing of a person's genome
for say $100,000. If Scan data is available on family mem-
bers, then this partial sequencing information from one
or two family members can be propagated throughout the
kindred. Wealthy individuals may decide to pay for such
sequencing out of pocket as a gift to their families. The
same principle holds for any other high-information,
high-cost tests, like for example, use of a 500,000 SNP
chip.
Concluding comments
From the human and other genome projects, we have
learned that whole genome approaches are nearly always
more efficient than strategies in which portions of the
genome are studied independently. This has been demon-
strated for genetic and physical mapping as well as
genomic sequencing. I argue that it is also time to switch
to a genome wide approach for clinical DNA testing. The
current clinical genetics approach of separate counseling,
DNA collection, and testing for each locus is hopelessly
inefficient if our goal is to substantially increase use of
genetic information in health care. Universal genetic tests
that can be performed in large numbers of patients are
vastly more cost efficient than personalized genetic tests.
The Genome Polymorphism Scan certainly qualifies as
such a universal test. It covers all genes in all individuals.
Despite the clinical promise of comparative genome
hybridization, this and other currently affordable genome
wide tests do not even come close to the number of appli-
cations described in this article. If the Scans were per-
formed on large numbers of patients, then the resulting
data would also comprise a vast pool of information that
could be mined for research purposes. We have the neces-
sary financial resources and technology. I believe we
should begin immediately.
Abbreviations
Scan Genome Polymorphism Scan
cM centiMorgan
STR short tandem repeat
STRPs short tandem repeat polymorphisms
SNPs single nucleotide (base substitution) polymor-
phisms
CGH comparative genomic hybridization
Reviewers' comments
Reviewer's report 1
Scott T. Weiss, M.D., M.S., Professor of Medicine, Harvard
Medical School, Boston, MA, USA
Weber provides a comprehensive review of Genome Poly-
morphism Scans in his review article. He has extensive
experience in this area having run the microsatellite geno-
typing service for NHLBI for over 10 years and having per-
formed many of these scans. He identifies 14 different
potential uses for STRP scans of varying density, and he
comprehensively covers the world of scanning from the
viewpoint of the genotyper. Despite the wealth of infor-
mation in the article there are other perspectives that
would have provided greater comprehensiveness to this
review and greater information for the reader.Biology Direct 2006, 1:16 http://www.biology-direct.com/content/1/1/16
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For example, who you genotype (ie your study design) is
as important as what type of markers and the marker den-
sity you use. Do you have a single family? A collection of
affected sib pairs? Extended pedigrees? What is the goal of
your scan? Do you wish to perform linkage for a complex
trait? Map a single gene disorder? Weber doesn't address
study design at all for the 14 different types of scans. Nor
does he provide the reader with what he would recom-
mend for each of his 14 applications, leaving the novice
to wonder about how best to approach each problem.
This results in several controversial and potentially con-
fusing points.
For example use of SNPs (diallelic markers) for linkage is
still controversial, especially for extended pedigrees,
because statistical software to analyze this data is still not
really available. Also, for association mapping it is
unlikely that 8000 markers (4 × 2000) is really enough to
cover the whole genome. It would cover a sizable region
for LD mapping of a linkage peak.
Despite these deficiencies the paper distills a wealth of
experience with genome scans from an experienced prac-
titioner of the art and presents a comprehensive delinea-
tion of its potential uses in genetics.
Reviewer's report 2
Roberta A. Pagon, M.D, Professor of Pediatrics, University of
Washington, and Division of Genetics and Development M2-9
Children's Hospital and Regional Medical Center Seattle, WA,
USA
Dr. Weber raises provocative and, I think still futuristic,
comments about the use of Genome Polymorphism Scans
("Scans) in clinical care. Scans, defined as the typing of a
set of DNA polymorphisms spanning the length of each
chromosome within a genome, provide a set of informa-
tion about normal variants in an individual, which Dr.
Weber calls a "universal test". Most current clinical molec-
ular genetic testing, by his definition, is "personalized
genetic testing", i.e., it is focused on identifying in an indi-
vidual specific disease-causing alleles to (1) establish dis-
ease causation or (2) establish disease risk based on
family history or race/ethnicity. Research testing for (1)
and (2) are totally different issues; as is forensic testing.
One can look at the clinical (not forensic, not research)
uses for Scans regarding their ability to accomplish (1)
and (2) above.
A strength of the proposed current clinical use of Scans is
that linkage disequilibrium can offer a prediction for cer-
tain mutations within a gene.
Weaknesses in the proposed current clinical use of Scans
are:
In general, in the current social and health payer environ-
ment, most testing needs to be done on individuals, not
families. The logistics of sample collection on far flung
families are problematic and in the US third party payer
reimbursement on testing of relatives (not probands) is
almost insurmountable.
Scans are limited in the ability to identify disease-causing
genetic alterations. They may be able to identify segmen-
tal aneusomy (but additional testing is likely to be neces-
sary to interpret the results with certainty). Furthermore,
current research with comparative genomic array analysis
has identified copy number to be a polymorphism that
confounds test result interpretation and has underscored
the comment of Dr Weber that the software needs for such
analysis are just beginning to be addressed.
Tracking multiple disease risk alleles (for common com-
plex disorders, such as diabetes mellitus, coronary artery
disease) in a family has great future potential, but limited
current application because the search for these disease
risk alleles, the ability to interpret their significance for
individuals, and the understanding of dietary/health/
environmental interventions that can reduce the risk itself
are still in the discovery stage.
The use of Scans in healthcare will require vast amounts of
genomic data and phenotype data that are updated as
individuals age. These significant issues are beginning to
be addressed at the national level by the National Insti-
tutes of Health, so there is no doubt that clinical applica-
tions of genomic polymorphism scan data will be useful
in healthcare, the question is when.
Reviewer's report 3
Val C. Sheffield, M.D., Ph.D., Professor of Pediatrics, Univer-
sity of Iowa, Iowa City, USA
In this article, Dr. James L. Weber reviews methods and
applications of a whole genome polymorphism scan and
expresses his opinion that a whole genome scan is the
most powerful clinical DNA test available today. Dr.
Weber expresses his opinion that a genome scan at a min-
imum density of one marker every 4 centimorgans is a
clinically useful and cost effective test, and he concludes
that such a genome-wide polymorphism scan should be
applied widely and that "we should begin immediately".
The article is an expansion and follow-up on an article
written by Dr. Weber in 1994 entitled "Know Thy
Genome". The current article expands upon the previous
article by reviewing more in depth current applications ofBiology Direct 2006, 1:16 http://www.biology-direct.com/content/1/1/16
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a genome scan. Dr. Weber correctly points out applica-
tions of genome-wide polymorphism scans, some of
which will be unfamiliar to some readers. These applica-
tions include, among others, gender determination, chi-
merism discovery, aneusomy detection, uniparental
disomy detection, autozygosity determination, geoances-
try estimation, and disease linkage and association detec-
tion. The author is correct that genome-wide scans are a
powerful tool and useful for many applications. The
author also correctly points out that large-scale genome-
wide approaches are more cost effective than small-scale
testing. The article is well referenced. The article makes
several interesting points, some of which are controver-
sial, and thus will be interesting to the readership.
The article has weaknesses which should be addressed by
the author. A major weakness is that the author does not
point out that there are major differences between
research applications of a genome scan and clinical appli-
cations. This weakness is most notable in the section on
"Limitations and Obstacles". In this section, the author
does not include some of the most significant obstacles to
the application of large-scale genome-wide genotyping to
clinical care. In his previous article, the author mentioned
such obstacles as genetic discrimination and privacy.
These issues are not mentioned in the current article. A
brief update of where things currently stand with respect
to these issues would improve the article.
The author ignores other important issues, and a more
balanced recognition of obstacles to applying a genome
scan to clinical care would strengthen the article. A few
other important obstacles that the author should address
to strengthen the article and give a more balanced picture
are mentioned below:
Although cost is discussed, the true cost of using a genome
scan as a clinical test is not considered. The author makes
estimates of the cost of the genome scan and based on
these costs describes the cost as affordable. The cost of the
actual genotyping is likely affordable. However, clinical
applications of the genome scan require sophisticated
analyses of polymorphism data and most importantly,
proper clinical interpretation of the data. The cost of this
interpretation is not considered.
Perhaps the most significant obstacle to the application of
a genome scan is the complexity of the data generated by
the scan. A genome-wide scan as proposed in the article
would contain numerous individual pieces of informa-
tion, as well as combinations of information that would
need to be integrated. The amount of data generated, in
fact, is the strength of the scan. But it is also the weakness.
Each individual interpretable piece of information gener-
ated by the scan would potentially have its own sensitivity
and specificity. In many cases, the sensitivity and specifi-
city would be population and/or family specific. Who in
the health care system would deliver the proper interpre-
tation to patients and by what means would the informa-
tion be delivered? It should be noted that currently genetic
counseling services are poorly reimbursed by third party
payers. The author makes an intriguing comment when he
states that "The current clinical genetics approach of sepa-
rate counseling...is hopelessly inefficient". Discussion of
alternative strategies would be of interest.
In recommending widespread application of a genome
scan for clinical purposes, the author ignores many of the
principles of current screening programs. Two such issues
include the availability of a useful intervention (treat-
ment) and the availability of societal infrastructure to
inform the patient and family of results, confirm results,
and properly implement treatment and counseling. It is of
interest that two of the tests mentioned by Dr. Weber as
potentially included in the scan are hemochromatosis and
apolipoprotein E (APOE) genotyping. Hemochromatosis
is a treatable disorder, but large-scale screening for this
disorder has not been implemented primarily because of
issues related to non-penetrance of the disorder, and thus
what a positive test means to a given individual. APOE
genotyping is not generally offered, even though specific
alleles are statistically associated with Alzheimer disease
and macular degeneration, for several reasons, primarily
that there is currently no specific successful intervention
for these disorders. The inclusion of this testing in a
genome-wide scan would at the present time have poten-
tially negative consequences. Dr. Weber's thoughts on
these issues would strengthen the article.
In summary, this article is a review of current applications
of genome-wide scans. The author makes interesting and
valid arguments regarding the utility of such scans for clin-
ical purposes. The major weakness is that the article does
not discuss important obstacles to the clinical application
of such a scan. Despite this weakness, I recommend
acceptance. The article will help generate important dia-
logue regarding the wide-spread application of clinical
genetic testing. By stating that "we should begin immedi-
ately", Dr. Weber has challenged the medical and scien-
tific community to intensity the effort to use genomic data
for patient care; the science education community to bet-
ter educate the public concerning the meaning of genetic
information; and each individual to be more involved
and responsible for their own health.
Author's response
I am grateful to the distinguished Reviewers for their thoughtful
comments. Nearly all of the Reviewers' concerns deal not with
the genetic and technical issues that are the primary focus of
this article, but rather with the practical difficulties involved inBiology Direct 2006, 1:16 http://www.biology-direct.com/content/1/1/16
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introducing the Scans into our health care system. I originally
planned to include my thoughts about the future of clinical
genetics in this review article, but it seemed that the article was
becoming too long. I decided therefore that it would be better to
split the material into two manuscripts: this review article deal-
ing with the genetic applications and technical issues of the
Scans, and a second perspective article dealing with what I
believe should be some of the next major steps in clinical genet-
ics, including of course introduction of the Scans. The second
manuscript is in preparation. All of the concerns raised by the
Reviewers will be addressed in the second manuscript. At this
point, I'll just state that although I agree completely with the
Reviewers that there are substantial obstacles to the introduc-
tion of the Scans into clinical practice, I also feel that the obsta-
cles are definitely surmountable, and that the time to begin
working on these problems is now.
Dr. Sheffield argues that some DNA analysis like HFE (hemo-
chromatosis) and APOE (Alzheimer Disease) testing is poten-
tially harmful. While I acknowledge that genetic
discrimination and overinterpretation of testing results are
potentially significant problems, I also respectfully submit that
the basic limitation of clinical genetics today is not too much
knowledge of patient's genomes, but rather too little. I believe
that a major objective of 21st century health care should be to
determine the complete or near complete genomic sequence of
virtually every patient. This is, of course, the primary rationale
behind all the money and efforts that are currently being
devoted to achieving the "$1,000 genome".
Finally, Dr. Weiss makes the valid point that low marker den-
sity Scans will have quite limited power to detect association.
Even at low marker density, however, the Scans will be able to
detect association for some genes that are close to the markers,
particularly in isolated populations. Hopefully, genotyping tech-
nology and marker density will eventually improve to the point
that association with nearly all genes becomes practical.
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